Cedars-Sinai Cancer investigators have identified two new treatment options for men with recurrent prostate cancer—both of which helped patients live longer without their disease progressing than the current standard treatment.
A five-year retrospective study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center shows that prostate-specific membrane antigen PET/CT scans can help doctors target treatment more precisely for men whose prostate cancer returns after surgery, improving long-term outcomes and potentially reducing unnecessary side effects.
